35
a
0.125–
0.75
5–20
N/A
N/R
2.5–5
N/A
N/A
10–15
N/A
t½: 2.5 h; hepatic
t½: 2–3 min;
hepatic
t½: 2–20 min; renal,
hepatic, plasma
↑
↑
↑
↑
↑
↑
↑
↑
↑
↓
↔
↓
↑
↔
SVR
Effects
HR
↑
CO
↓
↔
↔
↔
↔
Caution: MAO-I
Special
Considerations
Tachyarrhythmias, ↓BP
Renal dosing, monitor LFTs
Caution: MAO-I
↑/↓ BP, headache,
tachyarrhythmias, nausea, CI: sulfite allergy
fever, hypersensitivity
Tachyarrhythmias,
headache, nausea, tissue
necrosis
PVR Adverse Effects
t½ indicates elimination half-life; BP, blood pressure; CI, contraindication; CO, cardiac output; HF, heart failure; HR, heart rate; LFT, liver function test; MAO-I,
monoamine oxidase inhibitor; N/A, not applicable; N/R, not recommended; PDE, phosphodiesterase; PVR, pulmonary vascular resistance; SVR, systemic vascular
resistance.
Milrinone
PDE Inhibitor
Dobutamine
Dopamine
Infusion, Drug Kinetics &
min
Metabolism
5–10
Bolus
Dose, mcg/kg
Adrenergic Agonists
Inotropic
Agent
Table 21. Intravenous Inotropic Agents Used in Management of HFa
